← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extrac (CSF p-tau217 (biomarker), lncRNA-0021, astrocyte-derived extracellular vesicles) — 0.00 TREM2-Mediated Oligodendrocyte-Microglia Metabolic Coupling (TREM2) — 0.00 Closed-loop transcranial focused ultrasound with real-time g (PVALB) — 0.00 Closed-loop transcranial focused ultrasound to restore hippo (AQP4) — 0.00 Gamma-Entrained PV Interneurons Enable p-tau217-Guided Preci (lncRNA-0021, PVALB, CREB1) — 0.00 Age-Dependent TREM2 Signaling Disrupts Astrocyte-Microglia C (TREM2) — 0.00 Novel Hypothesis on Metabolic Dysregulation in Neurodegenera (SLC16A1 (MCT1)) — 0.00 Alpha-Beta Oscillation Entrainment Enhances lncRNA-9969-Medi (SST, CREB1, lncRNA-9969, PGC1α, TFAM, NRF1) — 0.00 APOE-TREM2 Ligand Availability Dysfunction in Neurodegenerat (APOE) — 0.00 Metabolic Reprogramming to Reverse Senescence (SIRT1,PGC1A,NAMPT) — 1.00 Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 1.00 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 1.00 Closed-loop transcranial focused ultrasound to restore hippo (PVALB) — 1.00 Closed-loop tACS targeting EC-II SST interneurons to block t (SST) — 1.00 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.99 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.99 Closed-loop tACS targeting EC-II PV interneurons to suppress (PVALB) — 0.99 SASP Modulation Rather Than Cell Elimination (NFKB1,IL1B,BDNF) — 0.98 Beta-frequency entrainment therapy targeting PV interneuron- (SST) — 0.98 LRP1-Dependent Tau Uptake Disruption (LRP1) — 0.98 Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte (SST, SSTR1, SSTR2) — 0.97 Closed-loop tACS targeting EC-II parvalbumin interneurons to (PVALB) — 0.97 PLCG2 Allosteric Modulation as a Precision Therapeutic for T (PLCG2) — 0.94 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.94 Dual-Receptor Antibody Shuttling (%s) — 0.94 SASP-Driven Microglial Metabolic Reprogramming in Synaptic P (HK2/PFKFB3) — 0.93 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.93 Closed-loop transcranial alternating current stimulation to (SST) — 0.93 Autophagy-Senescence Axis Therapeutic Window (ATG7,BCL2,BCL2L1) — 0.92 Palmitoylethanolamide-Based Endocannabinoid Therapy (PPARA) — 0.92
Add
|
× Test: TREM2 enhances amyl
- · - · -
Composite 0.400
Price $0.41
Evidence For 0
Evidence Against 0
**Background and Rationale**
Test: TREM2 enhances amyloid clearance is a mechanistic proposition centered on the idea that perturbation of TREM2-linked biology can materially shift disease trajectory in Alzheimer's disease. In modern neurodegeneration research, strong hypotheses are expected to bridge molecular mechanism, cell-state behavior, tissue-level pathology, and clinical manifestation. This description expands the starting hypothesis into a full translational narrative suitable for Exch
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Test: TREM2 enhances amyloid c Mechanistic 0.500 Evidence 0.000 Novelty 0.000 Feasibility 0.000 Impact 0.000 Druggability 0.000 Safety 0.000 Competition 0.000 Data 0.500 Reproducible 0.000
Evidence Test: TREM2 enhances amyloid clearance No evidence citations yet
Price History Overlay